NOVABAY PHARMACEUTICALS |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0757 USD | -2.07% |
|
-9.88% | -62.89% |
| Mar. 26 | Transcript : NovaBay Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 26, 2024 | |
| Mar. 26 | NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Evolution of the average Target Price on NovaBay Pharmaceuticals
Price target over the last 5 years
History of analyst recommendation changes
c51aa59c9cef6fcb84372562614e5.fNDZU6Mf-IJv_AsO5P-4oNUlvLkJ8Te--rkgOquvsd0.N7aICtl7kMAmuzhZloz3zbFR489QnmPkjIhOXc_LyOQ0lJ0S11qB0ifNXg~44c9ad8445d376a51b6753329765102d
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0773
USD
Average target price
2.6
USD
Spread / Average Target
+3,263.52%
High Price Target
3.2
USD
Spread / Highest target
+4,039.72%
Low Price Target
2
USD
Spread / Lowest Target
+2,487.32%
Consensus detail
Consensus revision (last 18 months)
Analysts covering NovaBay Pharmaceuticals
| Ladenburg Thalmann |
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
- Stock Market
- Equities
- NBY Stock
- Consensus NovaBay Pharmaceuticals
